Evidence map›Paper›PMID 26406445›Full record

Trial reportPloS one2015

Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2.

Sophie Blein, Laure Barjhoux, GENESIS investigators, Francesca Damiola, Marie-Gabrielle Dondon, Séverine Eon-Marchais, Morgane Marcou, Olivier Caron, Alain Lortholary, Bruno Buecher and 11 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Sophie BleinINSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Laure BarjhouxINSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
GENESIS investigators
Francesca DamiolaINSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Marie-Gabrielle DondonInserm, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France.
Séverine Eon-MarchaisInserm, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France.
Morgane MarcouInserm, U900, Paris, France.
Olivier CaronConsultation de Génétique, Département de Médecine, Institut de Cancérologie Gustave Roussy, Villejuif, France.
Alain LortholaryCentre Catherine de Sienne, Nantes, France.
Bruno BuecherInstitut Curie, Department of Tumour Biology, Paris, France.
Philippe VenninDépartement de Cancérologie sénologique, CLCC Oscar Lambret, Lille, France.
Pascaline BerthetCentre François Baclesse, Caen, France.
Catherine NoguèsOncogénétique Clinique, Hôpital René Huguenin/Institut Curie, Saint-Cloud, France.
Christine LassetUniversité Lyon 1, CNRS UMR5558, Lyon, France; Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France.
Marion Gauthier-VillarsConsultation de Génétique, Département de Médecine, Institut de Cancérologie Gustave Roussy, Villejuif, France.
Sylvie MazoyerINSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Dominique Stoppa-LyonnetConsultation de Génétique, Département de Médecine, Institut de Cancérologie Gustave Roussy, Villejuif, France; Institut Curie, INSERM U830, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France.
Nadine AndrieuInserm, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France.
Gilles ThomasUniversité Lyon 1, INCa-Synergie, Centre Léon Bérard, 28 rue Laennec, Lyon Cedex 08, France.
Olga M SinilnikovaINSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France; Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon - Centre Léon Bérard, Lyon, France.
David G CoxINSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Université Claude Bernard Lyon 1 · FRInserm · FRCentre François Baclesse · FRCentre Oscar Lambret · FRDélégation Paris 5 · FRHôpital René Huguenin · FRInstitut Curie · FRInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast Cancer is a complex multifactorial disease for which high-penetrance mutations have been identified. Approaches used to date have identified genomic features explaining about 50% of breast cancer heritability. A number of low- to medium penetrance alleles (per-allele odds ratio < 1.5 and 4.0, respectively) have been identified, suggesting that the remaining heritability is likely to be explained by the cumulative effect of such alleles and/or by rare high-penetrance alleles. Relatively few studies have specifically explored the mitochondrial genome for variants potentially implicated in breast cancer risk. For these reasons, we propose an exploration of the variability of the mitochondrial genome in individuals diagnosed with breast cancer, having a positive breast cancer family history but testing negative for BRCA1/2 pathogenic mutations. We sequenced the mitochondrial genome of 436 index breast cancer cases from the GENESIS study. As expected, no pathogenic genomic pattern common to the 436 women included in our study was observed. The mitochondrial genes MT-ATP6 and MT-CYB were observed to carry the highest number of variants in the study. The proteins encoded by these genes are involved in the structure of the mitochondrial respiration chain, and variants in these genes may impact reactive oxygen species production contributing to carcinogenesis. More functional and epidemiological studies are needed to further investigate to what extent variants identified may influence familial breast cancer risk.

Indexed as

BRCA1 ProteinBRCA2 ProteinMutationBreast NeoplasmsFemaleGenome, MitochondrialHigh-Throughput Nucleotide SequencingHumansMitochondrial Proton-Translocating ATPasesPenetranceBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanMitochondrial Proton-Translocating ATPasesMT-ATP6 protein, human

Identifiers

PMID26406445
PMCPMC4583250
OpenAlexW2181288376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.